Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam-β-Lactamase Inhibitor Combination

Impeding, as well as reducing, the burden of antimicrobial resistance in Gram-negative pathogens is an urgent public health endeavor. Our current antibiotic armamentarium is dwindling, while major resistance determinants (e.g., extended-spectrum β-lactamases [ESBLs]) continue to evolve and dissemina...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antimicrobial agents and chemotherapy 2019-05, Vol.63 (5)
Hauptverfasser:	Papp-Wallace, Krisztina M, Bethel, Christopher R, Caillon, Jocelyne, Barnes, Melissa D, Potel, Gilles, Bajaksouzian, Saralee, Rutter, Joseph D, Reghal, Amokrane, Shapiro, Stuart, Taracila, Magdalena A, Jacobs, Michael R, Bonomo, Robert A, Jacqueline, Cédric
Format:	Artikel
Sprache:	eng
Schlagworte:	Azabicyclo Compounds Azabicyclo Compounds - pharmacology beta-Lactamase Inhibitors beta-Lactamase Inhibitors - pharmacology Cefepime Cefepime - pharmacology Enterobacteriaceae Enterobacteriaceae - drug effects Enterobacteriaceae - metabolism Experimental Therapeutics Piperacillin, Tazobactam Drug Combination Piperacillin, Tazobactam Drug Combination - pharmacology Spectrometry, Mass, Electrospray Ionization Sulbactam Sulbactam - pharmacology Triazoles Triazoles - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!